Jazz Pharmaceuticals to Present Xywav Narcolepsy Data at 2026 AAN Annual Meeting
New poster presentation will detail self-reported outcomes in patients with narcolepsy treated with high dosages of low-sodium oxybate in the DUET study.
New poster presentation will detail self-reported outcomes in patients with narcolepsy treated with high dosages of low-sodium oxybate in the DUET study.
Avadel Pharmaceuticals has licensed valiloxybate from XWPharma Ltd.
The approval of the extended-release formulation of sodium oxybate allows for uninterrupted sleep and full treatment benefits in a single bedtime dose for people with narcolepsy.
Jazz Pharmaceuticals reported record third-quarter 2024 revenues of over $1.05 billion, with strong performance from its sleep portfolio.
Read MoreTop-line results show improvements on excessive daytime sleepiness and key polysomnography outcomes.
Read MoreA US court ruling supports the FDA’s approval of the once-nightly narcolepsy drug Lumryz, following a lawsuit by Jazz Pharmaceuticals challenging the drug’s orphan status and clinical superiority.
Read MoreSurvey data demonstrate that 94% of people with narcolepsy prefer the once-nightly regimen of Lumryz over twice-nightly oxybate regimens.
Read MoreNearly one in five study participants treated with the extended-release sodium oxybate medication experienced clinically meaningful weight loss.
Read MoreJazz reports second-quarter earnings, with growth driven in part by a 13% increase in Xywav sales.
Read MoreResearchers analyze Xywav and Xyrem’s population pharmacokinetic and exposure-responses, shining light on the dosing and titration of oxybates.
Read MoreTwo new studies reveal that narcolepsy is an independent risk factor for cardiovascular disease and adverse cardiac events.
Read MoreResearch includes phase 4 study design of low-sodium oxybate, Xywav efficacy in narcolepsy with psychiatric and neurologic comorbidities, and assessments of idiopathic hypersomnia burden.
Read MoreAvadel will present a series of new analyses highlighting the efficacy, safety, and patient preference for Lumryz, a once-nightly, extended-release formulation of sodium oxybate.
Read MoreThe research includes an oral presentation revealing that individuals with idiopathic hypersomnia experienced higher odds of comorbid conditions, such as cardiovascular disease.
Read MoreA jury from the United States District Court for the District of Delaware delivered a mixed verdict in a patent lawsuit between Jazz Pharmaceuticals Inc and Avadel Pharmaceuticals plc concerning Avadel’s narcolepsy medication Lumryz.
Read MoreSleep specialists share practical tips on choosing medications that treat narcolepsy symptoms, including excessive daytime sleepiness and cataplexy.
Read MoreJazz Pharmaceuticals announced new data highlighting the importance of low-sodium treatment options to help manage cardiovascular risk in patients with narcolepsy and idiopathic hypersomnia.
Read MoreAt World Sleep 2023, Jazz Pharmaceuticals will spotlight the link between sleep disorders and cardiovascular health through 14 abstracts.
Read More